文献速递浆细胞疾病

初治多发性骨髓瘤患者序贯治疗期间及之后的生活质量:英国医学研究委员会骨髓瘤IX随机研究结果

Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study.
PubMed 文献 · Br J Haematol · 2018-07-09

英国医学研究委员会骨髓瘤IX随机研究比较了氯膦酸钠与唑来膦酸、CVAD与CTD诱导方案及沙利度胺与观察维持对患者报告健康相关生活质量的影响,采用EORTC QLQ-C30和QLQ-MY24问卷在基线、3、6、12个月及之后每年评估。强化治疗路径中CTD在3个月疲乏和12个月躯体功能方面显著优于CVAD;非强化路径和维持阶段3个月时,疼痛(减量CTD改善)和总体健康状况/生活质量(观察改善)存在显著差异。

要点

  • 强化路径中CTD组3个月疲乏和12个月躯体功能显著优于CVAD组。
  • 非强化路径3个月时减量CTD组疼痛改善,观察组总体健康状况/生活质量改善。
  • 骨髓瘤IX研究疗效改善伴随部分有益且少数有害的健康相关生活质量影响。

核心结论

  • 骨髓瘤IX研究中疗效改善伴随部分有益且少数有害的健康相关生活质量影响。

研究设计与样本

  • 英国医学研究委员会骨髓瘤IX随机试验(ISRCTN684564111)将患者随机分配至氯膦酸钠或唑来膦酸,强化路径接受CVAD或CTD诱导后自体干细胞移植,非强化路径接受减量CTD或美法仑联合泼尼松龙,随后随机分配至沙利度胺或观察。
  • 采用EORTC QLQ-C30和QLQ-MY24问卷在基线、3、6、12个月及之后每年评估健康相关生活质量。
  • 方案设定疼痛、疲乏、总体健康状况/生活质量和躯体功能四个子量表在3、6、12个月时采用线性模型比较。

主要发现

  • 强化路径中,CTD组在3个月疲乏和12个月躯体功能方面显著优于CVAD组。
  • 非强化路径3个月时,减量CTD组疼痛改善,观察组总体健康状况/生活质量改善,差异显著。
  • 维持阶段3个月时,观察组总体健康状况/生活质量改善显著。

关键数值与推荐

  • 强化路径:3个月疲乏和12个月躯体功能,CTD组显著优于CVAD组。
  • 非强化路径:3个月疼痛,减量CTD组改善显著;3个月总体健康状况/生活质量,观察组改善显著。
  • 维持阶段:3个月总体健康状况/生活质量,观察组改善显著。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the Medical Research Council (MRC) Myeloma IX trial (ISRCTN684564111) patients were randomised to sodium clodronate or zoledronic acid and induction treatment: cyclophosphamide, vincristine, doxorubicin and dexamethasone (CVAD) or cyclophosphamide, thalidomide and dexamethasone (CTD) followed by autologous stem cell transplant (ASCT) in the intensive pathway; attenuated CTD or melphalan and prednisolone (MP) in the non-intensive pathway. Subsequent randomisation allocated patients to either thalidomide or observation. The European Organisation for Research and Treatment of Cancer (EORTC) quality of life (QoL) questionnaires, QLQ-C30 and QLQ-MY24, were administered at baseline, 3, 6 and 12 months and annually thereafter, enabling the effect of sequential treatment on patient-reported health-related QoL (HR-QoL) to be investigated. The protocol specified four subscales of interest: Pain, Fatigue, Global Health Status/Quality of Life and Physical Functioning at 3, 6 and 12 months that were compared using linear models. The intensive pathway showed significant differences in favour of CTD for Fatigue at 3 months and Physical Functioning at 12 months. The non-intensive pathway and maintenance phase reported significant differences at 3 months; Pain (improved with attenuated CTD) and Global Health status/Quality of Life (improved with observation). The improved outcomes in MRC Myeloma IX were accompanied by some beneficial and few detrimental effects on HR-QoL.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Royle KL, Gregory WM, Cairns DA, et al. Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study. Br J Haematol. 2018. PMID: 29984830. doi:10.1111/bjh.15459

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。